Find an expert

Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.

Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:

• Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
• Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
• Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.

With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).

Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.

Dr Jessica Schults is a Queensland Government Clinical Research Fellow and incoming NHMRC Emerging Leadership Fellow (2026) based at the Herston Infectious Diseases Institute and The University of Queensland. A previous paediatric critical care nurse, Jessica has extensive clinical experience in critical care, with a particular passion for ventilator associated infections. Jessica’s research program aims to reduce the burden of healthcare-associated infections through better hospital surveillance, safer invasive device care, and rapid translation of evidence. She is a Chief Investigator on the IVCare adaptive platform trial, which evaluates strategies to prevent catheter-related bloodstream infections, and leads the NHMRC-funded REBUILD project, which aims to strengthen national infection control systems using a learning health system approach. Jessica has a strong interest in the application of digital technologies, including AI-enabled risk prediction and clinical decision support tools. Jessica has strong, established partnerships with national and international healthcare consumers, organisations, and health services. She holds leadership roles with the Australian and New Zealand Intensive Care Society, is a board member for the ANZ Intensive Care Foundation and is a technical advisor to the Australian Commission on Safety and Quality in Health Care. Jessica is committed to growing the next generation of clinician-researchers, in-particular, in the underrepresented field of nursing.

I graduated with a degree in Chemical Engineering and Science in 2000 from The University of Queensland, after which I joined Proteome Systems, an Australian biotechnology company. In 2004 I moved to the ETH Zurich in Switzerland for my doctoral studies. I joined the School of Chemistry & Molecular Biosciences as a University of Queensland Postdoctoral Research Fellow in 2008 and NHMRC Career Development Fellow in 2012. I am now Associate Professor in Biochemistry.

Ian Scott is the Director of Internal Medicine and Clinical Epidemiology at the Princess Alexandra Hospital and a Professor with the Faculty of Medicine. He is a consultant general physician with clinical interests in in health services evaluation and improvement, clinical guidelines, clinical decision-making, evidence-based medicine, low value care, quality use of medicines, non-invasive cardiology, advance care planning, and older patient care. He chaired the Queensland Clinical Networks Executive 2022-2024, is the inaugural chair of the Australian Deprescribing Network (2014-2023), Metro South Clinical AI Working Group, and Queensland Health Sepsis AI Working Group (both ongoing) and is a founding member of the Australian and New Zealand Affiliate of the US Society to Improve Diagnosis in Medicine (ANZA-SIDM). He was also a member of Queensland Health System Quality, Safety and Performance Management Committee (2022-2024) and the Quality and Safety Committee (2015-2020) and the Digital Health Advisory Group of the Royal Australasian College of Physicians (RACP - ongoing). He is a past President of the Internal Medicine Society of Australia and New Zealand (2003-2005) and past member of the MBS Review Taskforce for Cardiac Services (2017-2019). He has led multi-site quality improvement collaboratives in acute cardiac care including both hospitals and Divisions of General Practice. He has been involved at senior level on various high-level committees in establishing policies for Queensland Health and/or RACP on electronic discharge summaries, clinical handover, clinical indicators, evaluation of physician performance, chronic disease management, perioperative medicine, medical assessment and planning units, and patient flow through emergency departments. He has published over 300 peer-reviewed articles, presented to over 170 national and international meetings, and is a recipient of several NHMRC and government research grants.

Dr Shakti Shrestha is a Lecturer in Pharmacy Practice and Medicines Management at the School of Pharmacy and Pharmaceutical Sciences, The University of Queensland (UQ) and undertakes course coordination for the First Semester Bachelor of Pharmacy program - PHRM1101. Shakti shifted to this full time academic role from a Research Fellow position that mainly involved conducting and supporting an Australian Government funded (Dementia Ageing and Aged Care Mission Medical Research Future Fund) research on improving the Quality Use of Medicine in Australian Residential Aged Care via the role of knowledge broker pharmacist (the EMBRACE project). Within his Research Fellow role, Shakti course coordinated Second Year teachout courses for UQ's Bachelor of Pharmacy program.

Shakti obtained his PhD at UQ School of Pharmacy, which focused on optimising medication use in older adults with limited life expectancy, drawing his extensive experience working and researching in a clinical medicine and aged care environment. He was a recipient of the 2018 Australian Research Training Scholarship at UQ for his doctoral degree. He also received the 2022 Career Development Scholarship from UQ that allowed him to develop clinical trial skills at Queensland Health, Sunshine Coast University Hospital, Townsville University Hospital and Gold Coast Private Hospital.

Shakti received his Master's degree in Clinical Pharmacology from the University of Aberdeen (UK) in 2010 and had an opportunity to work with the International Stroke Registry data called SITS-ISTR (Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Registry) in the National Health Service (NHS) Grampian Hospital, UK. He received his undergraduate Pharmacy degree from Pokhara University (Nepal) in 2007 and is registered as a Pharmacist both in Nepal and Australia.

Shakti has supervised nine pharmacy undergraduate thesis (4-years BPharm program) to completion in Nepal, and supervised several undergraduate and masters research project students. He continues to supervise a number of independent research projects mainly with the intention to support the capacity building of health professionals in research; these research often make into publications.

Shakti has research expertise in the field of geriatric and palliative medication use and safety, quality use of medicine, pharmacy practice and health services. He has research methodology expertise on systematic review, clinical research design, predictive model development, meta-analysis, medical statistics and qualitative research. He has more than 10 years of experience working in research, academic and clinical roles nationally and internationally.

Peter holds a BSc Honours degree and a PhD in Molecular Biology from the University of Liverpool in the UK. His first postdoctoral research position was at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, London UK. He moved to Australia in 2005 and helped Professor Lakhani establish the Molecular Breast Pathology research group and the Brisbane Breast Bank. He is a member of the International Cancer Genome Consortium (Breast Cancer group) and is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia. He holds a joint teaching and research position at UQ, teaching for the Discipline of Pathology on the Faculty of Medicine MD Program and is the Head of the Cancer Theme and Research Group Leader in Cancer Genomics at the UQCCR.

PLEASE NOTE THAT ANY AUTHORSHIP ALTERATIONS LISTING ME AS SIMPSON-FRASER BELOW ARE INCORRECT. ALL PUBLICATIONS ARE FIONA SIMPSON. MY PROFESSIONAL NAME IS FIONA SIMPSON.

https://www.abc.net.au/radionational/programs/ockhamsrazor/the-tricky-business-of-cancer-research/9498246

Our laboratory is involved in cross-discipline research studying endocytosis, cancer, pharmacology and immunology to improve therapies used in cancer treatment.

Professor Peter Sly is the Director, Children's Health and Environment Program. Professor Sly is a NHMRC Leadership Fellow (L3) and an emeritus paediatric respiratory physician with extensive research experience in respiratory physiology, developmental immunology and children's environmental health. Professor Sly’s research aims to understand the mechanisms underlying chronic childhood lung diseases in order to improve clinical management and to delay or prevent their onset, with consequent reductions in adult lung diseases. A combination of basic science, longitudinal cohort studies and translation of research findings into clinical practice, including clinical trials, are included in three main areas: asthma, cystic fibrosis and children’s environmental health

Professor Sly is an advisor to the World Health Organisation Department of Public Health, Environmental and Social Determinants of Disease and currently serves on International Advisory Boards and committees, including: WHO network of Collaborating Centres in Children’s Environmental Health; Canadian Healthy Infant Longitudinal Development (CHILD) Study, Canada; the Infant Lung Health Study, Paarl, South Africa; and A SHARED Future: Achieving Strength, Health, and Autonomy, through Renewable Energy Development for the Future.

Michelle Smith is a Associate Professor in Physiotherapy and a Titled Sports and Exercise Physiotherapist. She is Program Director for the Masters of Sports Physiotherapy and Masters of Musculoskeletal Physiotherapy programs at UQ, Co-director of the International Ankle Consortium, Co-director of the Sports Injury Rehabilitation and Prevention for Health (SIRPH) research unit and Associate Editor of Physical Therapy and Sport.

The overarching theme of Michelle's research is lower limb joint health. Her research focuses on the prevention and management of lower limb joint injuries and pathologies across the lifespan to enable unrestricted participation in sport, physical activity and work. There are three key areas of her research:

1. To improve understanding of ankle injuries and osteoarthritis across the lifespan: Ankle sprains are the most common injury seen in emergency departments and are a primary cause of ankle osteoarthritis, which in light of its post-traumatic nature, often affects young adults. To optimise outcomes and participation for people with ankle pathologies, my research characterises impairments and participation restrictions in the continuum from ankle injury to osteoarthritis and establishes the efficacy of interventions to manage these conditions.
2. To understand the effectiveness and implementation of injury prevention strategies: While neuromuscular exercise program and taping/bracing have been shown to decrease injury risk, translation of research into practice is limited. My research investigates the implementation of injury prevention initiatives in adolescent athletes and involves stakeholders to better understand barriers and facilitators.
3. To evaluate the implementation of lower limb osteoarthritis interventions: Exercise and education for hip and knee osteoarthritis have been shown to improve quality of life and functional outcomes. My research investigates the implementation of such programs in public hospitals and private physiotherapy practices on patient outcomes and service delivery.

Michelle has presented her research and delivered keynote and invited presentations at national and international multi-disciplinary conferences. She teaches across the undergraduate and postgraduate physiotherapy curriculum in the areas of musculoskeletal health and sports injuries. She has been recognised for her high teaching quality and impact at both School and Faculty levels through receipt of Teaching Excellence Awards. She is the Chair of the School of Health and Rehabilitation Sciences External Engagement Committee and Deputy Chair of the Sports and Exercise Physiotherapy Group of the Austrailan Physiotherapy Association. She is a member of the Outcome Measures in Rheumatology (OMERACT) Foot and Ankle Working Group, International Foot and Ankle Osteoarthritis Consortium, and Australian Foot and Ankle Research Network.

My group works to understand and improve sleep for children and families. Sleep is a key ‘pillar of health’ alongside nutrition and activity. It is critical for healthy development, growth, learning, social and emotional functioning, and community participation.

I am the UQ Node Director for the ARC Centre of Excellence for Children and Families over the Life Course (the Life Course Centre). The Life Course Centre is committed to understanding and overcoming the problems of disadvantage, and to helping improve the lives of disadvantaged children and families. The Centre brings together researchers across multiple disciplines in four leading Universities, and significant government and non-government agencies to address these questions.

I am also the UQ Node director for the ARC centre of Excellence for the Digital Child. The Digital Child aims to support children growing up in the rapidly changing digital world, and provide strong evidence and guidance for children, families, educators, government and other concerned with children’s wellbeing.

We collaborate with many other groups around broader issues of sleep and technology, sleep and the environment (including disasters), mental health and wellbeing, pain, disability, and new technologies and approaches. Our work has been supported by the ARC, NHMRC, the MRFF, the NIH, and the DSTG. We use a wide range of methods and measures, including direct physiological and behavioural measurement (inc. ECG, EEG, EMG, actigraphy, computerized tests, simulations, environmental monitoring etc.), quantitative methods (inc. experimental and secondary data approaches), and qualitative methods including co-design and co-conduct approaches.

My team has additional expertise in evaluation of health and other services for government and other agencies, the design of complex interventions, and community consultation and engagement.

https://lifecoursecentre.org.au

https://digitalchild.org.au

Dr Smith is an early career researcher and Registrar in Intensive Care Medicine at RBWH and Mater Hospitals. Despite being at an early stage in his medical and research career, Sam has already gained valuable experience and enthusiasm in medical education and research, crossing clinical and methodological domains.

Dr Smith gained his primary medical qualification at James Cook University, graduating in 2019 with Honours and awards in research/ Evidence Based Medicine, rural medicine, and with the Dr D. Graham Prize for the highest marks in surgical examinations. His Honours research, supervised by Professor Jonathan Golledge, focussed on the economic impacts of readmission after surgery for peripheral artery disease (PAD). For this research, he was awarded the Professor Philip Walker Scholarship in Vascular Research, allowing him to present his findings internationally. He has co-authored papers in vascular and cardiothoracic surgery, tropical infectious diseases, and care of critically unwell and trauma patients.

Aside from clinical duties, Sam is also active in teaching, guest lecturing at James Cook University and the University of Queensland, as well as teaching medical students in the clinical setting. In his clinical practice, Sam has developing interests in critical care medicine, vascular access, POCUS and incorporating best evidence into daily practice. His committment to teaching, research and governance led to Dr Smith being awarded the CPMEC QLD Junior Doctor of the Year Award in 2021. Sam is always very keen to share his enthusiasm for all things evidence-based with students or really anyone who will listen.

Qualifications

• MBBS (Hons.)
• MPH&TM

Emeritus Professor Mark Smithers is a surgical oncologist who specialises in surgery for oesophago-gastric diseases, melanoma, advanced skin cancer and soft tissue sarcoma. He was the Director of the Upper GI and Soft Tissue Unit at the Princess Alexandra Hospital, in Brisbane, Australia from 1998 - 2023. Commencing his academic career with the University of Queensland in 1987, he progressed to be the Mayne Chair in Surgery and head of the Academy of Surgery. He is the second University of Queensland Medical graduate to be appointed to this role. His research has been focussed on the development and assessment of outcomes from minimally invasive upper GI surgery, and trials assessing the role of perioperative multidisciplinary therapy for esophageal and gastric cancer. As well he has led, or been involved with, clinical trials from phase I to III, for all stages of melanoma through his role as the Chair of the Queensland Melanoma Project. More recently he has been involved with the assessment of access to, and outcomes from, surgery for cancer in Queensland, Australia.

He has overseen the administration and development of the surgery curriculum, and the teaching, in the Academy of Surgery, in the UQ Faculty of Medicine. He was on a number of committees relevant to the implementation of the UQ MD design course. He has held various leadership and committee roles with the Royal Australasian College of Surgeons, as well as leadership roles, including the Presidency, in the Australian and New Zealand Oesophago Gastric Surgeons Association. He has also been on the committees of international organisations related to oesophageal and gastric surgery. He has published 250 articles, eight book chapters, and has been on the editorial board of a number of surgical journals.

He has been recognised for his clinical and academic roles by the award of Member of the Order of Australia (AM). The citation reads, "for service to medicine in the fields of gastro-intestinal and melanoma surgery, to medical education and to professional organisations". The Royal Australasian College of Surgeons awarded him the Sir Hugh Devine medal, for services to surgery and the community. This is the College’s highest honour. Internationally, he has been awarded an honorary fellowship of the Royal College of Surgeons of Edinburgh and recently, in the United States, he was elected as an Honarary Fellow of the American Surgical Association.

Professor Soyer is an academic dermatologist with over 30 years experience in the field. He was appointed as the inaugural Chair in Dermatology by The University of Queensland (UQ) in 2007 and was Director of the Princess Alexandra Hospital (PAH) Dermatology Department from 2008-2023. His clinical background drives a strong focus on translational skin cancer research.

Professor Soyer is internationally recognised in the field of dermatology with particular expertise in the areas of preventative dermatooncology, dermatopathology and dermatologic imaging (dermoscopy and reflectance confocal microscopy). Within the dermatology discipline he is a pioneer and world leader in the field of dermoscopy of pigmented skin lesions, a non-invasive diagnostic method. He has led the development of the morphologic classification system currently used worldwide.

His main research focus is skin cancer (both melanoma and keratinocyte skin cancer), with a particular interest in technological innovations and their ability to impact early detection strategies and expand the concept and applications of teledermatology and teledermoscopy. A $9.9M infrastructure grant awarded in 2018 by the Australian Cancer Research Foundation (ACRF) has enabled establishment of the collaborative Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID); installing 15 3D total body imaging systems, linked by a research network, across Australia’s east cost to facilitate research in the early detection of melanoma. ACRF ACEMID is currently conducting Australia’s largest melanoma cohort study targeting 15,000 participants, with the multi-modal research data being collected and stored in a national research repository. This unprecedented data resource will allow many unanswered research questions in the field to be addressed and will facilitate advancements in artificial intelligence, resulting in the development of reliable, evidence-based solutions to transform melanoma early detection.

Professor Soyer has an extensive publication record with over 680 publications to date, with more than 700 citations per year (in the last 5 years) and an h-index of 96 (Google Scholar). His textbook entitled "Dermoscopy - The Essentials 3rd Edition", co-authored with G Argenziano, R Hofmann-Wellenhof and I Zalaudek is considered a world-leading textbook in the field.

Professor Soyer has been awarded two competitive fellowships while at UQ: a Medical Research Future Fund (MRFF) Next Generation Clinical Researchers Program Practitioner Fellowship (2018-2022) and an NHMRC Practitioner Fellowship (2012-2016). The NHMRC Practitioner Fellowship was acknowledged in the NHMRC ‘10 of the Best NHMRC research projects 2016’ publication. He has also been awarded 1 NHMRC European Union Collaborative Research Grant (CIA), 1 NHMRC Synergy Grant (CIC), 1 NHMRC Clinical Trials and Cohort Studies Grant (CIC), 1 MRFF Targeted Health System and Community Organisation Research Grant (CIC), 3 NHMRC Centre of Research Excellence Grants (CIA, CIB, CIE), 4 NHMRC Project Grants (CIA, CIA, CIB, CID), 2 NHMRC Partnership Grants (CIA, CIB), 2 ARC Discovery Project Grants (CIB, CID), and a Queensland Genomic Health Alliance (QGHA) Demonstration Project Grant (CIA), with many additional projects funded through other competitive, industry and philanthropic funding sources. In total, through his involvement as an investigator, he has achieved over $43M in research funding for UQ since 2014.

Associate Professor Spurling works at The University of Queensland General Practice Clinical Unit (0.4 FTE) and at the Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander primary health care (Inala COE – 0.6 FTE). He has research interests in social determinants of health and access to primary health care, especially where his research skills can be of service to Aboriginal and Torres Strait Islander peoples. His other research interests are quality use of medicines and respiratory infections, with particular methodological interests in systematic reviews and mixed-methods research in general practice. His most recent research interest concerns access to opioid dependence treatment in general practice.

He completed medical training at the University of Queensland, did his junior doctor years in regional Queensland and completed a Diploma of Tropical Medicine and Hygiene in London in 1998. In 2001, he spent 12 months working on a project in Central America with Médecins Sans Frontières. He completed general practice specialty training with the RACGP in 2004, which included an academic registrar term. In 2004, he was fortunate to meet Professor Noel Hayman, one of Queensland’s first Aboriginal medical graduates and Clinical Director of the Inala COE, who offered him a GP position in 2004. He has shared his full-time work as a GP academic at the Inala COE and UQ GPCU ever since.

Associate Professor Spurling has developed clinical interests in serving the Aboriginal and Torres Strait Islander community in Inala, serving Spanish-speaking refugees, diabetic retinopathy, and, most recently, addiction medicine. He has been mentoring GP registrars and medical students at the Inala COE since 2004. As a member of the UQ GPCU academic staff, he regularly takes tutorial groups and lectures in cardiovascular medicine, respiratory infections, Aboriginal and Torres Strait Islander health and social determinants of health for medical students doing their general practice rotation.

Associate Professor Spurling supervises five postgraduate students (PhD students). He has been awarded over A$18M in research grants and has published over 80 peer-reviewed papers.

Christine graduated with a Bachelor of Pharmacy degree (honours class 1) from the University of Queensland in 1996.

She registered as a pharmacist in Australia in 1997 and in the United Kingdom in 2003 and has worked at the Redlands, Princess Alexandra and Wesley Hospitals in Brisbane and the Western Infirmary in Glasgow. In 2002 she was awarded a PhD from the University of Queensland, with a thesis focusing on improving usage of the immunosuppressant agent tacrolimus in solid organ transplant recipients.

In 2004 she was the recipient of a National Health and Medical Research Council (NHMRC) Neil Hamilton Fairley fellowship. This award enabled her to training overseas in the field of Pharmacometrics within the Department of Medicine and Therapeutics at the University of Glasgow (Scotland) and the Department of Pharmaceutical Biosciences at Uppsala University (Sweden).

On her return to Brisbane, Christine was the recipient of a Lions Medical Research Fellowship and was the chief investigator on a three year NHMRC Project Grant. She has also been a team member on an Amgen-Transplant Society of Australia and New Zealand Research Grant and a Cellcept Australia Research Grant. Over her research career Christine has attracted grants and awards totaling more than 2 million AUD from various funding agencies.

Research Interests

Christine has a wide range of interests in the fields of Quality Use of Medicine and Pharmacometrics. Her work to date has primarily been directed towards optimising usage of immunosuppressant drugs in solid organ transplant recipients and antibiotics in patients with life-threatening infections.

Christine has published over 75 peer reviewed papers and 90 conference abstracts on these topics. Her publications have been cited on more than 3200 occasions, with twelve cited more than 50 times.

Christine has successfully supervised to completion fourteen higher research degree students and enjoys helping students meet their career goals.

Christine’s current projects include:

• Individualising immunosuppressant therapy in autoimmune disease to improve patient outcomes
• Comparing the efficacy and safety of continuous versus intermittent administration of beta-lactams in critically ill patients
• Examining the relationship between immunosuppression and non-melanoma skin cancer in renal transplant recipients
• Improving individualisation of immunosuppressant therapy in adult kidney transplant recipients
• Improving gentamycin dosing in paediatric oncology patients
• Examining tobramycin monitoring in cystic fibrosis patients in Australia and the United Kingdom
• Investigating the relationship between prednisolone exposure and drug-related toxicity in paediatric and adult kidney transplant recipients
• Comparing different therapeutic drug monitoring methods for dosage adjustment of once daily intravenous tobramycin treatment in children with cystic fibrosis

Projects currently available for interested research higher degree students include:

• Dose optimisation of busulfan in paediatric bone marrow transplant recipients
• Investigating the relationship between immunosupressant exposure and drug-related toxicity in transplant recipients
• Examining Bayesian forecasting methods to predict immunosuppressant exposure
• Examining the international use of immunosuppressant and anti-rheumatic drugs
• Examining the influence of plasma exchange on immunosuppressant drug exposure

Christine invites potential honours and post-graduate students to contact her via email to discuss research opportunities.

Teaching interests

Co-ordinates:

• PHRM3052- Biological Fate of Drugs

Teaches in:

• PHRM3052- Biological Fate of Drugs
• PHRM3011- Quality Use of Medicines

Assoc. Prof. Stephan is an anatomist and forensic anthropologist with research interests in skeletal analysis and identification in the medicolegal setting. Specifcally these research interests include: craniofacial identification, radiographic comparison, trauma, unmingling of skeletons, biological profile estimations and standards of practice. Carl heads the Laboratory for Human Craniofacial and Skeletal Identification (HuCS-ID Lab), and is Chief Anatomist at The University of Queensland (UQ) School of Anatomy.

Carl is a Fellow of The American Academy of Forensic Sciences and recent past President of the International Association of Craniofacial Identification. Carl served as Special Issue Managing Guest Editor for Forensic Science International, Latest Progress in Craniofacial Identification, 2018. He has been Editorial Board Member of the Journal of Forensic Sciences (2013-23) and Associate Editor of Forensic Anthropology (2016-20). Carl founded the SBMS Skeletal Collection and Skeletisation Program at UQ in late 2014, re-energising forensic osteology within the UQ School of Anatomy and more broadly within the School of Biomedical Sciences.

Carl's prior appointments include forensic anthropology analyst with the Iraq Mass Graves Investigation Team (USA Army Corps of Engineers on behalf of the USA Department of Justice) and ORISE researcher at the USA Department of Defence Central Identification Laboratory in Hawaii. He often now serves as an external consultant to the USA Defence POW/MIA Accounting Agency (DPAA). At UQ and as Chief Anatomist and School of Anatomy manager, Carl works very closely with the SBMS Gross Anatomy Facility, in all matters of anatomy teaching, research and governance management.

Working in joint with the GAF Manager, Carl has cross adapted ISO17025 style practices and auditing procedures to the UQ School of Anatomy space and introduced the first Code-of-Practice for Use of Human Tissues within the UQ School of Anatomy since its inauguration (1927). These accreditation-style policies and procedures are further implemented and expanded in the HuCS-ID Lab, providing vital learning experiences and skill sets for Honours and Higher Research Degree students wanting to pursue careers in forensic science. New data analytic, casework and research tools developed by the HuCS-ID Lab and in the statistical environment of R, are freely and routinely released for others to use at the website: CRANIOFACIALidentification.com.

Carl's research outputs currently exceed 100 total scientific publications, including more than 85 full-length research articles..

Michele Sterling is a NHMRC Leadership Fellow (leadership level 2), Professor in the Recover Injury Research Centre, Program Lead of the Musculoskeletal Injury research program and Director of the NHMRC Centre of Research Excellence (CRE) in Better Health Outcomes for Compensable Injury. She is a Musculoskeletal Physiotherapist and a Fellow of the Australian College of Physiotherapists. She is internationally recognised for her research on whiplash-associated disorders. Michele’s research focusses on the mechanisms underlying the development of chronic pain after injury, predictive algorithms for outcomes and developing effective interventions for musculoskeletal injury and pain. She has received over $50M in research funding from the NHMRC, MRFF, ARC and industry partners, including 7 NHMRC project grants, and 2 Centres of Research Excellence. Michele holds editorial roles with several leading journals and textbooks, including being a Section Editor of PAIN and co-editors of the 4th and 5th editions of the seminal physiotherapy textbook 'Grieve's Musculoskeletal Physiotherapy). Michele has published over 325 scientific works and has received numerous awards for her research including the Research Australia Research Translation award in 2023. Examples of recognition as a national and international leader in the field include:

2024- Secretary of the Executive Council - International Association for the Study of Pain (IASP)

2022-2024 Chair Scientific Program Committee World Pain Congress, Amsterdam 2024

2023-2027 NHMRC Leadership Fellow (Level 2) for research of road traffic injury.

2023 Research Australia Research Translation award

2016-2022 Council member International Association for the Study of Pain (IASP)

Associate Professor Steyn is a leading expert in neurodegenerative disease research, specializing in the metabolic and physiological aspects of Motor Neurone Disease (MND). He currently directs a comprehensive translational research program at the University of Queensland, focusing on the interplay between metabolism and disease progression in MND, and leads key projects investigating the impact of metabolic dysfunction, appetite dysregulation, and hypermetabolism on patient outcomes. His work prioritizes the integration of pre-clinical models, clinical studies, and innovative digital health technologies to advance understanding of the heterogeneity in MND, patient care and therapeutic development.

Associate Professor Steyn’s career began with detailed investigations into the hypothalamic regulation of energy homeostasis, growth, and reproduction. He developed industry-standard methodologies for evaluating hormone release patterns in rodent models, particularly concerning growth hormone regulation. In 2015, he transitioned to focus on neurodegenerative diseases, establishing a research platform at UQ that has significantly advanced the analysis of metabolic phenotypes in MND.

His current research projects include the MEND-MND study, which explores how altered energy metabolism influences disease progression, and the EATT4MND study, which examines the consequences of appetite loss and impaired body weight regulation on disease outcomes. Through collaboration with industry partners, he is also developing novel therapeutic strategies and refining wearable digital health technologies for precise, real-time monitoring of disease progression, including the validation of actigraphy-based measures as clinical trial biomarkers.

Professor Jennifer Stow is a molecular cell biologist, an NHMRC Leadership Fellow and head of the Protein Trafficking and Inflammation research laboratory in The University of Queensland’s Institute of Molecular Bioscience (IMB). Her previous leadership appointments include as Division Head and Deputy Director (Research) at IMB (12 years) and she currently serves on national and international advisory boards, editorial boards and steering committees, and as an elected Associate Member of the European Molecular Biology Organisation (EMBO).

Jenny Stow received her undergraduate and PhD qualifications at Melbourne’s Monash University before undertaking postdoctoral training in the Department of Cell Biology at Yale University School of Medicine, USA. With training as a microscopist in kidney research, she gained further experience at Yale as a postdoc in the lab of eminent cell biologist and microscopist, Dr Marilyn Farquhar, where protein trafficking was both a theme and a passion. Jenny then took up her first faculty appointment as an Assistant Professor in the Renal Unit at Massachusetts General Hospital (MGH) and Harvard Medical School in Boston USA, where her research uncovered new roles for a class of enzymes, GTPases, in regulating trafficking within cells. At MGH her research also formed part of a highly successful NIH Renal Cell Biology Program. In late 1994, Jenny moved her research lab back to Australia, to The University of Queensland, in late 1994 as a Wellcome Trust International Medical Research Fellow. As part of IMB since, the Stow lab has continued a focus on protein trafficking, including pioneering live-cell imaging, to spearhead their work on trafficking in inflammation, cancer and chronic disease. Major discoveries include identifying new proteins and pathways for recycling adhesion proteins in epithelial cells, inflammatory cytokine secretion in macrophages and immune signalling through Toll-like receptors in inflammation and infection. Small GTPases of the Rab family, signalling adaptors and kinases feature among the molecules studied in the Stow lab for their functional roles and their potential as drug targets in inflammation and cancer. A keen focus is to understand the role of the fluid uptake pathway, macropinocytosis, in controlling inflammation, cancer and mucosal absorption.

Professor Stow has been awarded multiple career fellowships including from American Heart Association, Wellcome Trust and NHMRC. She has published >200 papers, cited over 15,500 times and she is the recipient of awards and honours, most recently including the 2019 President's Medal from the Australia and New Zealand Society for Cell and Developmental Biology. She is also academic head of IMB Microscopy, a world-class fluorescence microscopy and image analysis facility. Her research is funded by a variety of agencies and industry partnerships, in addition to NHMRC and ARC, including through the ARC Centre of Excellence in Quantum Biotechnology, QUBIC. The Stow lab work with national and international collaborators and welcome students and postdoctoral trainees to participate in their research. We value having a diverse, inclusive and supportive culture for research and celebrate the many diverse and wonderful successes of Stow lab alumni.

MS has 35 years clinical research experience in pathogenesis and management of hypertension (HT), including endocrine varieties such as primary aldosteronism (PA). Working within the Greenslopes Hospital Hypertension Unit (GHHU), he helped demonstrate that PA is 10 times more common than previously thought and to account for approximately 10% of HT, making it the commonest specifically treatable, potentially curable variety, and in the description of a new familial form (FH-II) which recently led to the elucidation of its genetic basis (a gain of function mutation in CLCN2, published in Nature Genetics). The combined GHHU/Princess Alexandra Hospital HT Unit (PAHHU, which MS set up in 2000) has possibly the largest series (>2500) worldwide of patients with PA who have been thoroughly documented and meticulously studied, helping MS to become internationally recognized as an authority on pathogenesis/genetics, diagnostic workup and management of PA. In 2006, MS served as member of an international Task Force sponsored by the US Endocrine Society to develop the first guideline for diagnosis and management of PA (published in J Clin Endocrinol Metab and cited >1200 times with an update published in 2016 and cited >1900 times). He is currently Co-Chair of the working group for the third guideline. MS conceived, developed and validated the seated saline suppression test which has since become the favoured method for definitively confirming the diagnosis of PA in most Australian and in a rapidly growing number of overseas institutions. He has also made major contributions to the understanding of how various physiological and pharmacological factors affect the aldosterone/renin ratio as a screening test for PA and in optimizing approaches to adrenal venous sampling, the most reliable method of differentiating unilateral (surgically curable) from bilateral varieties.

Publications: MS has published 1 book, 20 textbook chapters and >250 papers in peer-reviewed scientific journals. His journal publications have been cited >14,000 times ("h" index 59).

Grant Support: Since 2019, MS has received ~$16 million in research grant support. He is currently a CI on two MRFF grants and an NHMRC CCRE.

Invited Presentations and Collaboration: MS has been invited to speak at major meetings 137 times (99 international) and has collaborated with researchers in >20 international Units and all Australian states. In 2018, was one of six investigators awarded a highly prestigious Leducq Foundation Transatlantic Networks of Excellence Program grant ($USD 6 million) to study the role of potassium in hypertension.

Committee Highlights: MS is past President of the Asian-Pacific Society of Hypertension and of the High Blood Pressure Research Council of Australia. During his time as HBPRCA President, initiatives that were introduced under his presidency included launching of a successful bid for 24h ABPM to be assigned an item number to enable a Medicare rebate of ABPM services. He was a Member of the NHF BP & Vascular Disease Advisory Committee 1998-2013.

Community Engagement: As President since 1995 of the Queensland Hypertension Association, a non-profit organization dedicated to promoting self-care in the management of hypertension, MS has overseen all of its activities, including bimonthly educational sessions and preparation of educational material for the general community and health professionals. On numerous occasions, MS has provided information to the community on issues related to hypertension by media interview.

Peer Review: Previously serving on Editorial Boards for of J Clin Endocrinol Metab, J Hypertens, Clin Exper Pharmacol Physiol, and Nephology, MS is currently Editor-in-Chief of J Hum Hypertens and a member of the Editorial Board for Hypertension. He has assessed 100’s of manuscripts for major international journals and served as grant application assessor on many occasions for major international and national funding bodies (including the NHMRC).

Other Awards and Honours: (1) John W.H. Tyrer Prize for Research in Internal Medicine, (2) Robert Vandongen Memorial Lecturer (University of WA), 2002, (3) Honorary Professor to the Xinjiang Institute of Hypertension, 2005, (4) Visiting Professor to the Tung Wah Eastern Hospital, Hong Kong, 2008, (5) Gaston Bauer Lecturer, Cardiac Society of Australia and New Zealand, 2012, (5) Nimmo Visitor, Royal Adelaide Hospital, 2015, (6) Paul Korner Award, Hypertension Australia, 2024.